Skip to main content

ALNY

Stock
Health Care
Biotechnology

Performance overview

ALNY Price
Price Chart

Forward-looking statistics

Beta
1.06
Risk
44.37%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Company info

SectorHealth Care
IndustryBiotechnology
Employees2K
Market cap$19.3B

Fundamentals

Enterprise value$42.6B
Revenue$2.3B
Revenue per employee—
Profit margin-11.49%
Debt to equity2358.26

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.09
Dividend per share—
Revenue per share$18.27
Avg trading volume (30 day)$294M
Avg trading volume (10 day)$315M
Put-call ratio—

Macro factor sensitivity

Growth+1.3
Credit+14.5
Liquidity-3.0
Inflation-3.4
Commodities+1.1
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-272.06
Price to sales18.43
P/E Ratio-272.06
Enterprise Value to Revenue18.15
Price to book374.62

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

Benzinga (July 1, 2025)
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Zacks Investment Research (June 10, 2025)
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.

CNBC Television (March 31, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free